Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences

GAITHERSBURG, Md., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences during the fourth quarter and early portion of the first quarter of 2019:

• JP Morgan – 2018 CEO Conference Call Series
  Virtual/Conference Call (information to be provided by JP Morgan)
  November 13, 2018
  
  
• Three Part Advisors – 2018 Southwest IDEAS Investor Conference
  Dallas, TX
  November 14-15, 2018
  
  
• Piper Jaffray – 30^th Annual Healthcare Conference
  New York, NY
  November 27-29, 2018
  
  
• Mizuho – Global Mizuho Investor Conference
  New York, NY
  December 3, 2018
  
  
• BMO Capital Markets – 2018 Prescriptions for Success Healthcare Conference
  New York, NY
  December 12, 2018
  
  
• JP Morgan – 37^th Annual Healthcare Conference
  San Francisco, CA
  January 7-10, 2019

Presentation dates and times will be updated on the Emergent website www.emergentbiosolutions.com under “Investors” as the information becomes available.
For these conferences, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website.

About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. We aspire to be a Fortune 500 company recognized for protecting and enhancing life, driving innovation, and living our values. Additional information about the company may be found at www.emergentbiosolutions.com. Find us on LinkedIn and follow us on Twitter @emergentbiosolu and Instagram @life_at_emergent.

Investor Contact:
Robert G. Burrows
Vice President, Investor Relations
240-631-3280
[email protected]

Media Contact:
Lynn Kieffer
Vice President, Corporate Communications
240-631-3391
[email protected]

You May Also Be Interested In

• BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates
• Viking Holdings Ltd (VIK) Tops Q2 EPS by 36c